{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["59(1)"],"submitter":["Ottosen S"],"pubmed_abstract":["Miravirsen is a β-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). Miravirsen demonstrated antiviral activity against hepatitis C virus (HCV) genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 μM. No cytotoxicity was observed up to the highest concentration tested (>320 μM) in different cell culture models, yielding a therapeutic index of ≥ 297. Combination studies of miravirsen with interferon α2b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions. Miravirsen demonstrated broad antiviral activity when tested against HCV replicons resistant to NS3, NS5A, and NS5B inhibito"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["599-608"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4291405"],"repository":["biostudies-literature"],"pubmed_title":["In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122."],"pmcid":["PMC4291405"],"pubmed_authors":["Yang L","Patick AK","van der Veer E","Hodges MR","Parsley TB","van Doorn LJ","Ottosen S","Zeh K","Raney AK"],"additional_accession":[]},"is_claimable":false,"name":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.","description":"Miravirsen is a β-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). Miravirsen demonstrated antiviral activity against hepatitis C virus (HCV) genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 μM. No cytotoxicity was observed up to the highest concentration tested (>320 μM) in different cell culture models, yielding a therapeutic index of ≥ 297. Combination studies of miravirsen with interferon α2b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions. Miravirsen demonstrated broad antiviral activity when tested against HCV replicons resistant to NS3, NS5A, and NS5B inhibito","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2025-04-04T08:20:22.648Z","creation":"2019-03-27T01:43:16Z"},"accession":"S-EPMC4291405","cross_references":{"pubmed":["25385103"],"doi":["10.1128/aac.04220-14","10.1128/AAC.04220-14"]}}